Biomarkers for ovarian cancer ctap3-related proteins

Abstract

The present invention provides a protein-based biomarker that is useful in qualifying ovarian cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarker can be detected by SELDI mass spectrometry.

1 - 35 . (canceled) 
     
     
         36 . A method of detecting a panel of biomarkers in a sample from a subject, comprising:
 contacting the sample from the subject to a substrate;   binding a panel of biomarkers in the sample from the subject to capture reagents, wherein the capture reagents are attached to the substrate,   
       wherein the panel of biomarkers consists of biomarkers selected from the group consisting of:
 (a) ApoA1, Beta-2 microglobulin, transthyretin, transferrin, and CA125; 
 (b) Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125); 
 (c) Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125), and transferrin or transthyretin; and 
 (d) Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125), transferrin, and transthyretin, 
 
       thereby detecting the panel of biomarkers in the sample from the subject. 
     
     
         37 . The method of  claim 36 , wherein the detecting occurs by a technique selected from the group consisting of: immunoassay; mass spectrometry; and combinations thereof. 
     
     
         38 . The method of  claim 37 , wherein the immunoassay technique is selected from the group consisting of: fluorescence-based immunoassay; enzyme immunoassay; nephelometry; and SELDI-based immunoassay. 
     
     
         39 . The method of  claim 37 , wherein the mass spectrometry technique is selected from the group consisting of: Surface-Enhanced Laser Desorption and Ionization (SELDI); Surface-Enhanced Neat Desorption (SEND); Surface-Enhanced Photolabile Attachment and Release (SEPAR); Matrix-Assisted Laser Desorption/Ionization (MALDI); Liquid Chromatography (LC-MS); and Liquid Chromatography-LC-MS (LC-LC-MS). 
     
     
         40 . The method of  claim 37 , wherein the detecting occurs by a combination of immunoassay and mass spectrometry. 
     
     
         41 . The method of  claim 36 , wherein the capture reagents are selected from the group consisting of: antibodies, SELDI probes, immobilized metal chelates (IMACs), single or double stranded oligonucleotide, amino acid, protein, peptide, and fragments thereof. 
     
     
         42 . The method of  claim 36 , wherein the capture reagents are selected from the group consisting of: antibodies, aptamer, and Affibody. 
     
     
         43 . The method of  claim 36 , wherein the capture reagents are antibodies. 
     
     
         44 . The method of  claim 36 , wherein the substrate is a solid phase. 
     
     
         45 . The method of  claim 44 , wherein the solid phase is selected from the group consisting of: a bead, a plate, a membrane, an array, a biochip, a SELDI probe. 
     
     
         46 . The method of  claim 45 , wherein the plate is a microtiter plate. 
     
     
         47 . The method of  claim 36 , wherein the capture reagents are antibodies and the substrate is a microtiter plate. 
     
     
         48 . The method of  claim 36 , wherein the sample is blood or a blood derivative. 
     
     
         49 . The method of  claim 48 , wherein the blood derivative is serum. 
     
     
         50 . The method of  claim 36 , wherein the subject is at risk of developing ovarian cancer. 
     
     
         51 . The method of  claim 36 , wherein the subject suffers from ovarian cancer. 
     
     
         52 . The method of  claim 36 , wherein the panel of biomarkers consists of: ApoA1, Beta-2 microglobulin, transthyretin, transferrin, and CA125. 
     
     
         53 . The method of  claim 36 , wherein the panel of biomarkers consists of: Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125). 
     
     
         54 . The method of  claim 36 , wherein the panel of biomarkers consists of: Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125), and transferrin or transthyretin. 
     
     
         55 . The method of  claim 36 , wherein the panel of biomarkers consists of: Apolipoprotein A1 (ApoA1), Beta-2 microglobulin, Human Epididymis Protein 4 (HE4), and Cancer Antigen 125 (CA125), transferrin, and transthyretin.